Metabolic Syndrome Severity Score  in Subjects with and without Poly Cystic Ovarian Syndrome

Sikandar Hayat Hhan; Ayesha Hafeez; Rahat Shahid; Chaudhry Qamar Ul Haq Noor; Javeria Hafeez; Mehreen Gillani

doi:10.51253/pafmj.v74i5.8626

Authors

Sikandar Hayat Hhan Department of Pathology, Pakistan Navy Ship Hafeez Hospital, Islamabad Pakistan
Ayesha Hafeez Department of Pathology, Combined Military Hospital Multan/National University of Medical Sciences (NUMS) Pakistan
Rahat Shahid Department of Radiology, Pakistan Navy Ship Hafeez Hospital, Islamabad Pakistan
Chaudhry Qamar Ul Haq Noor Medical Directorate, Naval Headquarters, Islamabad Pakistan
Javeria Hafeez Department of Dermatology, Combined Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Mehreen Gillani Department of Pathology, Pakistan Navy Ship Hafeez Hospital, Islamabad Pakistan

DOI:

https://doi.org/10.51253/pafmj.v74i5.8626

Keywords:

Homeostasis Model Assessment of insulin resistance (HOMA-IR), Metabolic Syndrome Severity Score (MSSS), Modified Ferriman Gallway Scoring (mFG score), Polycystic ovarian syndrome (PCOS), Rotterdam PCOS criteria.

Abstract

Objective: To compare polycystic ovarian syndrome and their defining criteria with metabolic syndrome severity score among females with and without polycystic ovarian syndrome.

Study Design: Comparative cross-sectional study.

Place and Duration of Study: Naval Hospital Islamabad, from Jan 2018 to Dec 2021.

Methodology: We evaluated 293 female subjects for Poly Cystic Ovarian Syndrome after several exclusions who presented with an initial complaint of disturbances in menstrual cycles. These subjects underwent clinical examination including blood pressure and anthropometric indices and measurements of modified Ferriman Gallway score. Biochemical measurements included fasting plasma glucose, HDL cholesterol, triglycerides and insulin measurement. These parameters were measured for various components included in defining the Poly Cystic Ovarian Syndrome as per Rotterdam criteria and Metabolic Syndrome Severity Score equation to compare metabolic syndrome severity and insulin resistance among subjects with Poly Cystic Ovarian Syndrome and without Poly Cystic Ovarian Syndrome.

Results: Mean age among participants were 29.46±6.74 years. Disturbances in menstrual cycle reporting oligo/anovulation was reported by (181/293) 61.8% in comparison to (112/293) 38.2%. Hirsutism (modified Ferriman Gallway score>8) was present in (142/293) 48.5%. Radiological findings pointing towards Poly Cystic Ovarian Syndrome diagnosis were found in (72/293) 24.6%. Metabolic Syndrome Severity Score showed higher correlation with age, and insulin resistance in contrast to hirsutism and free androgen indices. Hirsutism was higher among oligo/anovulation females than participants without menstrual complaints (14.17+8.99 vs. 11.16+7.88, p=0.004). Similarly, bioc

Conclusion: Metabolic Syndrome Severity Score equation does not associate with Poly Cystic Ovarian Syndrome criteria as defined by Rotterdam. Insulin resi

Downloads

Download data is not yet available.

References

Azziz R. Polycystic Ovary Syndrome. Obstet Gynecol 2018; 132(2): 321-336.

https://doi.org/10.1097/AOG.0000000000002698

Sekhon AK, Zergham AS, Tserenpil G, Mebasher A, Malik BH. The Association between Polycystic Ovary Syndrome and Its Dermatological Manifestations. Cureus 2020; 12(2): e6855.

https://doi.org/10.7759/cureus.6855

Chamberlain G, Wood C. Stein-Leventhal Syndrome. Br Med J 1964 ;1(5375): 96-98. https://doi.org/ 10.1136/bmj.1.5375.96

Rasquin Leon LI, Anastasopoulou C, Mayrin JV. Polycystic Ovarian Disease. 2021. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.

Wang J, Wu D, Guo H, Li M. Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome. Life Sci 2019; 236: 116940. https://doi.org/10.1016/j.lfs.2019.116940

Nolan CJ, Prentki M. Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift. Diab Vasc Dis Res 2019; 16(2): 118-127. https://doi.org/10.1177/1479164119827611

Moghetti P, Tosi F. Insulin resistance and PCOS: chicken or egg? J Endocrinol Invest 2021; 44(2): 233-244.

https://doi.org/10.1007/s40618-020-01351-0

Jeanes YM, Reeves S. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges. Nutr Res Rev 2017; 30(1):97-105. https://doi.org/10.1017/S0954422416000287

Bruni V, Capozzi A, Lello S. The Role of Genetics, Epigenetics and Lifestyle in Polycystic Ovary Syndrome Development: the State of the Art. Reprod Sci 2022; 29(3): 668-679. https://doi.org/10.1007/s43032-021-00515-4

Jeanes YM, Reeves S. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges. Nutr Res Rev 2017; 30(1): 97-105. https://doi.org/ 10.1017/S0954422416000287

Park PG, Pyo JY, Ahn SS, Song JJ, Park YB, Huh JH, et al. Metabolic Syndrome Severity Score, Comparable to Serum Creatinine, Could Predict the Occurrence of End-Stage Kidney Disease in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. J Clin Med 2021; 10(24): 5744. https://doi.org/ 10.3390/jcm10245744

Aswini R, Jayapalan S. Modified Ferriman-Gallwey Score in Hirsutism and its Association with Metabolic Syndrome. Int J Trichology 2017; 9(1): 7-13. https://doi.org/ 10.4103/ijt.ijt_93_16

Li W, Chen Q, Xie Y, Hu J, Yang S, Lin M. Prevalence and degree of insulin resistance in Chinese Han women with PCOS: Results from euglycemic-hyperinsulinemic clamps. Clin Endocrinol 2019; 90(1): 138-144. https://doi.org/10.1111/cen.13860

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81(1): 19-25.

Ali AT. Polycystic ovary syndrome and metabolic syndrome. Ceska Gynekol 2015; 80(4): 279-289.

Asato CBH, Nelson-Hurwitz DC, Lee T, Grandinetti A. Comparative Analysis of Metabolic Syndrome Diagnostic Criteria and Its Effects on Prevalence in a Multiethnic Population. Metab Syndr Relat Disord 2021 ;19(6):347-351. https://doi.org/10.1089/met.2020.0090

Lim SS, Kakoly NS, Tan JWJ, Fitzgerald G, Bahri Khomami M, Joham AE, et al. Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Obes Rev 2019; 20(2): 339-352.

https://doi.org/10.1111/obr.12762

Jamil AS, Alalaf SK, Al-Tawil NG, Al-Shawaf T. A case-control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. Reprod Health 2015 ;12: 7. https://doi.org/110.1186/1742-4755-12-7

Bil E, Dilbaz B, Cirik DA, Ozelci R, Ozkaya E, Dilbaz S. Metabolic syndrome and metabolic risk profile according to polycystic ovary syndrome phenotype. J Obstet Gynaecol Res 2016; 42(7): 837-843. https://doi.org/10.1111/jog.12985

Mimouni NEH, Paiva I, Barbotin AL, Timzoura FE, Plassard D, Le Gras S, et al. Polycystic ovary syndrome is transmitted via a transgenerational epigenetic process. Cell Metab 2021; 33(3): 513-530.e8. https://doi.org/10.1016/j.cmet.2021.01.004

Wawrzkiewicz-Jałowiecka A, Kowalczyk K, Trybek P, Jarosz T, Radosz P, Setlak M, et al. In Search of New Therapeutics-Molecular Aspects of the PCOS Pathophysiology: Genetics, Hormones, Metabolism and Beyond. Int J Mol Sci 2020 ;21(19):7054. https://doi.org/10.3390/ijms21197054

Toosy S, Sodi R, Pappachan JM. Lean polycystic ovary syndrome (PCOS): an evidence-based practical approach. J Diabetes Metab Disord 2018; 17(2):277-285.

https://doi.org/10.1007/s40200-018-0371-5

Stovall DW, Bailey AP, Pastore LM. Assessment of insulin resistance and impaired glucose tolerance in lean women with polycystic ovary syndrome. J Womens Health 2011 ;20(1):37-43. https://doi.org/10.1089/jwh.2010.2053